Loading...

Jacek K Pinski, MD, PhD

Title(s)Associate Professor of Medicine
Phone+1 323 865 3929
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    GlaxoSmithKline2001Fellowship Award
    Johns Hopkins University2001Fellowship Research Award
    American Association for Cancer Research2001Translational Research Award
    2001Stop Cancer Award Special Seed Award
    2002Wright Award
    2002ACS/IRG Award
    2002Whitney Award
    2002Stop Cancer Research Career Development Award

    Collapse Overview 
    Collapse Overview
    After completing a fellowship at the Johns Hopkins Cancer Center in Baltimore, Dr. Pinski came to the Keck School of Medicine at USC as an Assistant Professor of Medicine. A former Research Assistant Professor at the Endocrine, Polypeptide and Cancer Institute at the Tulane University School of Medicine, Dr. Pinski is currently the Co-Director of the USC/Norris Comprehensive Cancer Center’s Prostate Cancer Research Center.

    Dr. Pinski is also a member of the Rehabilitation Research and Development Section for the United States Department of Veteran Affairs. He has received funding for seven research studies and in 2006 was invited to lecture in Austraila at the 3rd Annual Pacific Rim Breast and Prostate Cancer Meeting. Dr. Pinski has had over 60 peer reviewed articles published and has given presentations all across the globe.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 Aug 09. PMID: 31398279.
      View in: PubMed
    2. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 Mar 19. PMID: 31227432.
      View in: PubMed
    3. Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 Jan 01; 25(1):43-51. PMID: 30232224.
      View in: PubMed
    4. Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. PMID: 29679564.
      View in: PubMed
    5. Yu SS, Athreya K, Liu SV, Schally AV, Tsao-Wei D, Groshen S, Quinn DI, Dorff TB, Xiong S, Engel J, Pinski J. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):742-749. PMID: 28668277.
      View in: PubMed
    6. Shahabi A, Lewinger JP, Ren J, April C, Sherrod AE, Hacia JG, Daneshmand S, Gill I, Pinski JK, Fan JB, Stern MC. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. Prostate. 2016 10; 76(14):1239-56. PMID: 27272349.
      View in: PubMed
    7. Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 10; 14(5):450-456.e1. PMID: 26935231.
      View in: PubMed
    8. Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski JK, Stern MC. Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era. Can Urol Assoc J. 2016 Jan-Feb; 10(1-2):E17-22. PMID: 26858782.
      View in: PubMed
    9. Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. PMID: 25693195.
      View in: PubMed
    10. Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski J. Effects of luteinizing hormone receptor signaling in prostate cancer cells. Prostate. 2015 Feb; 75(2):141-50. PMID: 25393079.
      View in: PubMed
    11. Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. PMID: 25278449.
      View in: PubMed
    12. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. PMID: 25245366.
      View in: PubMed
    13. Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res. 2014 May 15; 74(10):2857-68. PMID: 24648349.
      View in: PubMed
    14. Ingles SA, Liu SV, Pinski J. LHRH and LHR genotypes and prostate cancer incidence and survival. Int J Mol Epidemiol Genet. 2013; 4(4):228-34. PMID: 24319538.
      View in: PubMed
    15. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. PMID: 24238569.
      View in: PubMed
    16. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. PMID: 24099865.
      View in: PubMed
    17. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. PMID: 23785174.
      View in: PubMed
    18. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503.
      View in: PubMed
    19. Engel J, Emons G, Pinski J, Schally AV. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs. 2012 Jun; 21(6):891-9. PMID: 22577891.
      View in: PubMed
    20. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012 Apr 18; 4(2):420-41. PMID: 24213318.
      View in: PubMed
    21. Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J. Ethnic differences in neuroendocrine expression in prostate cancer tissue. Anticancer Res. 2011 Nov; 31(11):3897-901. PMID: 22110216.
      View in: PubMed
    22. Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. PMID: 21621934.
      View in: PubMed
    23. Dorff TB, Pinski J. Advanced prostate cancer: new agents, new questions. Oncology (Williston Park). 2011 May; 25(6):509, 512. PMID: 21717905.
      View in: PubMed
    24. Liu SV, Liu S, Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs. 2011 Jun; 20(6):769-78. PMID: 21449823.
      View in: PubMed
    25. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. PMID: 20142723.
      View in: PubMed
    26. Schally AV, Engel JB, Emons G, Block NL, Pinski J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv. 2011 Jan; 8(1):11-25. PMID: 21034424.
      View in: PubMed
    27. Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate. 2011 Jun 01; 71(8):892-8. PMID: 21456071.
      View in: PubMed
    28. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 01; 70(15):1692-700. PMID: 20564320.
      View in: PubMed
    29. Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. PMID: 20623636.
      View in: PubMed
    30. Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. PMID: 20670943.
      View in: PubMed
    31. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. PMID: 20484019.
      View in: PubMed
    32. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
      View in: PubMed
    33. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate. 2009 Jan 01; 69(1):12-23. PMID: 18814146.
      View in: PubMed
    34. Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV. Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate. 2008 Oct 01; 68(14):1555-60. PMID: 18651557.
      View in: PubMed
    35. Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. PMID: 18782306.
      View in: PubMed
    36. Cheung E, Wadhera P, Dorff T, Pinski J. Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. PMID: 18095882.
      View in: PubMed
    37. Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. PMID: 18383880.
      View in: PubMed
    38. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    39. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007 Oct; 38(10):1547-52. PMID: 17640713.
      View in: PubMed
    40. Dorff TB, Quek ML, Daneshmand S, Pinski J. Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. PMID: 17134367.
      View in: PubMed
    41. Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, Gentzschein E, Pinski JK, Stanczyk FZ, Jones PA, Coetzee GA. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol. 2006 Oct; 26(19):7331-41. PMID: 16980632.
      View in: PubMed
    42. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV. Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate. 2006 Aug 01; 66(11):1136-43. PMID: 16652383.
      View in: PubMed
    43. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. PMID: 16697447.
      View in: PubMed
    44. Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. PMID: 16221056.
      View in: PubMed
    45. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther. 2005 Jul; 4(7):1105-13. PMID: 16020668.
      View in: PubMed
    46. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 01; 65(11):4623-32. PMID: 15930280.
      View in: PubMed
    47. Daneshmand S, Dorff TB, Quek ML, Cai J, Pike MC, Nichols PW, Pinski J. Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology. 2005 May; 65(5):1008-12. PMID: 15882754.
      View in: PubMed
    48. Pinski J, Dorff TB. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer. 2005 Apr; 41(6):932-40. PMID: 15808959.
      View in: PubMed
    49. Jadvar H, Xiankui L, Shahinian A, Park R, Tohme M, Pinski J, Conti PS. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005 Apr-Jun; 4(2):91-7. PMID: 16105512.
      View in: PubMed
    50. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004 Dec; 172(6 Pt 1):2252-5. PMID: 15538242.
      View in: PubMed
    51. Wang Q, Horiatis D, Pinski J. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation. Prostate. 2004 Nov 01; 61(3):253-9. PMID: 15368468.
      View in: PubMed
    52. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer. 2004 Sep 10; 111(4):508-13. PMID: 15239127.
      View in: PubMed
    53. Horiatis D, Wang Q, Pinski J. A new screening system for proliferation-independent anti-cancer agents. Cancer Lett. 2004 Jul 08; 210(1):119-24. PMID: 15172129.
      View in: PubMed
    54. Jadvar H, Kherbache HM, Pinski JK, Conti PS. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol. 2003 Dec; 60(6):395-400. PMID: 14690256.
      View in: PubMed
    55. Jadvar H, Pinski JK, Conti PS. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. PMID: 12883728.
      View in: PubMed
    56. Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res. 2002 Feb 15; 62(4):986-9. PMID: 11861369.
      View in: PubMed
    57. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res. 2001 Sep 01; 61(17):6372-6. PMID: 11522628.
      View in: PubMed
    58. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer. 1998 Mar 01; 82(5):909-17. PMID: 9486581.
      View in: PubMed
    59. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate. 1997 Aug 01; 32(3):164-72. PMID: 9254895.
      View in: PubMed
    60. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 1997 Jun; 33(7):1141-8. PMID: 9376196.
      View in: PubMed
    61. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci U S A. 1997 May 27; 94(11):5810-3. PMID: 9159156.
      View in: PubMed
    62. Jungwirth A, Schally A, Nagy A, Pinski J, Groot K, Galvan G, Szepeshazi K, Halmos G. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol. 1997 May; 10(5):877-84. PMID: 21533457.
      View in: PubMed
    63. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-Buenfil M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer. 1997; 75(11):1585-92. PMID: 9184172.
      View in: PubMed
    64. Pinski J, Schally A, Jungwirth A, Groot K, Halmos G, Armatis P, Zarandi M, Vadillobuenfil M. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol. 1996 Dec; 9(6):1099-105. PMID: 21541617.
      View in: PubMed
    65. Pinski J, Izdebski J, Jungwirth A, Groot K, Schally AV. Effect of chronic administration of a new potent agonist of GH-RH(1-29)NH2 on linear growth and GH responsiveness in rats. Regul Pept. 1996 Sep 16; 65(3):197-201. PMID: 8897642.
      View in: PubMed
    66. Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology. 1996 Aug; 137(8):3430-6. PMID: 8754771.
      View in: PubMed
    67. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci U S A. 1996 Mar 19; 93(6):2398-402. PMID: 8637885.
      View in: PubMed
    68. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer. 1996 Mar 15; 65(6):870-4. PMID: 8631606.
      View in: PubMed
    69. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst. 1995 Dec 06; 87(23):1787-94. PMID: 7473836.
      View in: PubMed
    70. Schally AV, Halmos G, Pinski J. Terminology for luteinizing hormone-releasing hormone antagonists. Fertil Steril. 1995 Jul; 64(1):226. PMID: 7789575.
      View in: PubMed
    71. Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 1995 May 23; 92(11):4872-6. PMID: 7761415.
      View in: PubMed
    72. Pinski J, Schally AV, Yano T, Groot K, Srkalovic G, Serfozo P, Reissmann T, Bernd M, Deger W, Kutscher B. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75). Int J Pept Protein Res. 1995 May; 45(5):410-7. PMID: 7591480.
      View in: PubMed
    73. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A. 1994 Dec 06; 91(25):12298-302. PMID: 7991622.
      View in: PubMed
    74. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 1994 Nov 15; 54(22):5895-901. PMID: 7954420.
      View in: PubMed
    75. Shirahige Y, Cook C, Pinski J, Halmos G, Nair R, Schally A. Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice. Int J Oncol. 1994 Nov; 5(5):1031-5. PMID: 21559676.
      View in: PubMed
    76. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer. 1994 Nov; 70(5):886-92. PMID: 7947094.
      View in: PubMed
    77. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer. 1994 Oct 01; 59(1):51-5. PMID: 7927904.
      View in: PubMed
    78. Halmos G, Pinski J, Szoke B, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Lett. 1994 Sep 30; 85(1):111-8. PMID: 7923093.
      View in: PubMed
    79. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A. 1994 Jul 19; 91(15):7090-4. PMID: 7518926.
      View in: PubMed
    80. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer. 1994 May 15; 57(4):574-80. PMID: 7910153.
      View in: PubMed
    81. Yano T, Pinski J, Radulovic S, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1994 Mar 01; 91(5):1701-5. PMID: 8127868.
      View in: PubMed
    82. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 1994 Feb 15; 73(4):1229-38. PMID: 8313327.
      View in: PubMed
    83. O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, Carney DN. Somatostatin receptor expression in lung cancer. Eur J Cancer. 1994; 30A(11):1682-7. PMID: 7833144.
      View in: PubMed
    84. Pinski J, Reile H, Halmos G, Groot K, Schally AV. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res. 1994 Jan 01; 54(1):169-74. PMID: 7903203.
      View in: PubMed
    85. Shirahige Y, Cai RZ, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomed Pharmacother. 1994; 48(10):465-72. PMID: 7858155.
      View in: PubMed
    86. Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int J Cancer. 1993 Dec 02; 55(6):963-7. PMID: 7902829.
      View in: PubMed
    87. Pinski J, Halmos G, Szepeshazi K, Schally AV. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Cancer. 1993 Dec 01; 72(11):3263-70. PMID: 8242552.
      View in: PubMed
    88. Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV. Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486. J Clin Endocrinol Metab. 1993 Nov; 77(5):1388-92. PMID: 8077338.
      View in: PubMed
    89. Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett. 1993 Jul 30; 71(1-3):189-96. PMID: 8103419.
      View in: PubMed
    90. Pinski J, Yano T, Szepeshazi K, Groot K, Schally AV. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75). J Androl. 1993 May-Jun; 14(3):164-9. PMID: 8407570.
      View in: PubMed
    91. Pinski J, Yano T, Groot K, Zsigo J, Rekasi Z, Comaru-Schally AM, Schally AV. Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats. Int J Pept Protein Res. 1993 Mar; 41(3):246-9. PMID: 8463048.
      View in: PubMed
    92. Groot K, Csernus VJ, Pinski J, Zsigo J, Rekasi Z, Zarandi M, Schally AV. Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone. Int J Pept Protein Res. 1993 Feb; 41(2):162-8. PMID: 8458690.
      View in: PubMed
    93. Pinski J, Schally AV, Yano T, Szepeshazi K, Halmos G, Groot K, Comaru-Schally AM, Radulovic S, Nagy A. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate. 1993; 23(2):165-78. PMID: 8378189.
      View in: PubMed
    94. Pinski J, Yano T, Janaky T, Nagy A, Juhasz A, Bokser L, Groot K, Schally AV. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats. Int J Pept Protein Res. 1993 Jan; 41(1):66-73. PMID: 8436447.
      View in: PubMed
    95. Pinski J, Yano T, Schally AV. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinology. 1992 Dec; 56(6):831-7. PMID: 1369591.
      View in: PubMed
    96. Janáky T, Juhász A, Rékási Z, Serfözö P, Pinski J, Bokser L, Srkalovic G, Milovanovic S, Redding TW, Halmos G. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10203-7. PMID: 1332035.
      View in: PubMed
    97. Pinski J, Yano T, Rekasi Z, Cai RZ, Radulovic S, Schally AV. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regul Pept. 1992 Oct 13; 41(3):185-93. PMID: 1438988.
      View in: PubMed
    98. Pinski J, Yano T, Groot K, Cai RZ, Radulovic S, Schally AV. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats. Am J Physiol. 1992 Oct; 263(4 Pt 1):E712-7. PMID: 1415689.
      View in: PubMed
    99. Pinski J, Yano T, Groot K, Milovanovic S, Schally AV. Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. Peptides. 1992 Sep-Oct; 13(5):905-11. PMID: 1336188.
      View in: PubMed
    100. Yano T, Pinski J, Groot K, Schally AV. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res. 1992 Aug 15; 52(16):4545-7. PMID: 1643647.
      View in: PubMed
    101. Pinski J, Milovanovic S, Yano T, Hamaoui A, Radulovic S, Cai RZ, Schally AV. Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs. Proc Soc Exp Biol Med. 1992 May; 200(1):49-56. PMID: 1349189.
      View in: PubMed
    102. Cai RZ, Radulovic S, Pinski J, Nagy A, Redding TW, Olsen DB, Schally AV. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides. 1992 Mar-Apr; 13(2):267-71. PMID: 1409006.
      View in: PubMed
    103. Pinski J, Yano T, Miller G, Schally AV. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate. 1992; 20(3):213-24. PMID: 1533453.
      View in: PubMed
    104. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat. 1992; 21(1):35-45. PMID: 1391973.
      View in: PubMed
    105. Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Prostate. 1992; 20(4):297-310. PMID: 1351672.
      View in: PubMed
    106. Radulovic S, Cai RZ, Serfozo P, Groot K, Redding TW, Pinski J, Schally AV. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Protein Res. 1991 Dec; 38(6):593-600. PMID: 1726427.
      View in: PubMed